RE:A buck 20 off Analyst target? The only facts that have changed- were changed by management.
The 35% drop came from their statements vs their contrary actions.
Much like the years of touting DIMI/ SAMI- misleading shareholders with tales of an imminent trial- only to now happily disclose the pump was never up to clinical quality.
This company needs to stop playing games.
Realize that their lack of transparency has never worked out for them, and share the Tigris "crude data" with the market (and potential buyers) as they proclaimed multiple times and in writing.